Neurocrine Biosciences
NBIX
#1376
Rank
C$21.44 B
Marketcap
C$215.06
Share price
1.49%
Change (1 day)
19.63%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): C$6.01

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$6.01. In 2024 the company made an earnings per share (EPS) of C$4.71 an increase over its 2023 EPS that were of C$3.54.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$6.0127.59%
2024C$4.7133.07%
2023C$3.5457.76%
2022C$2.2569.47%
2021C$1.32-78.21%
2020C$6.08990%
2019C$0.5681.82%
2018C$0.31-113.5%
2017C-$2.270.62%
2016C-$2.2657.28%
2015C-$1.4425.61%
2014C-$1.1418.84%
2013C-$0.96-1085.71%
2012C$0.09762

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
C$0.04184-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.46-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
C-$85.06-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$28.61 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$1.89-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$2.40-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$2.38-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.83-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA